Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2015
At a glance
- Drugs S 38093 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors IRIS; Servier
- 21 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 13 Dec 2012 New source identified and integrated (United Kingdom Clinical Research Network; 11864).
- 08 Dec 2012 Additional lead trial centre identified as reported by European Clinical Trials Database.